DEF: Cosmos Health Seeks Shareholder Approval for Reverse Split, $300M Notes, and Expanded Equity Plan

Cosmos Health Inc. calls its 2025 Annual Meeting to vote on critical proposals including a discretionary reverse stock split, a $300 million convertible note issuance, and a new 2025 equity incentive plan.

Summary

• Shareholders will vote on eight key proposals at the Annual Meeting on September 30, 2025, including the election of six directors.
• The Board seeks authorization to effect a reverse stock split of common stock at its discretion, primarily to maintain Nasdaq listing compliance.
• Approval is requested for the issuance of common stock upon conversion of up to $300 million in 9% senior secured convertible promissory notes, in compliance with Nasdaq Listing Rule 5635(d).
• A new 2025 equity incentive plan, reserving 6,000,000 shares, requires shareholder approval to incentivize officers, employees, directors, and consultants.
• The company also seeks to increase authorized capital stock to 1,500,000,000 shares of Common Stock and 300,000,000 shares of blank check Preferred Stock.
• Net losses were $16,183,018 in 2024, $18,542,654 in 2023, and $13,830,371 in 2022.
• Total Shareholder Return (TSR) for an initial $100 investment declined to $48.8 in 2024 from $25.6 in 2023 and $4.8 in 2022 (note: the filing states $48.8 for 2024 and $25.6 for 2023, which implies an increase from 2023 to 2024, but a significant decline from the initial $100 investment over the three years).
• Executive compensation for CEO Grigorios Siokas totaled $2,904,100 in 2024, including $400,000 in bonus and $1,242,100 in stock awards.
• Several related party transactions are disclosed, including significant prepaid balances and receivables with Doc Pharma S.A., a company whose CEO is the wife of Cosmos Health's CEO.

Sentiment

Score: 3

Explanation: The sentiment is negative due to persistent net losses, declining shareholder return, the need for a reverse stock split to maintain listing, and significant dilution from a large convertible note offering. While there are growth initiatives and a new equity plan, the underlying financial performance and governance issues (late Section 16(a) filings) are concerning.

Positives

• The proposed 2025 equity incentive plan aims to strengthen commitment, attract new talent, and retain existing employees, officers, and directors by aligning their interests with shareholders.
• The Board of Directors unanimously recommends voting FOR all proposals, indicating internal alignment on these strategic initiatives.
• The company is actively pursuing new product development and commercialization, including 60 new Sky Premium Life licenses purchased in 2024 and an exclusive worldwide license for innovative cancer treatments.

Negatives

• The company reported significant net losses of $16,183,018 in 2024, $18,542,654 in 2023, and $13,830,371 in 2022, indicating ongoing unprofitability.
• Total Shareholder Return (TSR) for an initial $100 investment has declined significantly over the past three years, reaching $48.8 in 2024, reflecting poor stock performance.
• A reverse stock split is being considered primarily to maintain Nasdaq listing compliance, suggesting the stock price has been below the minimum bid requirement.
• The issuance of shares upon conversion of the $300 million notes and the increase in authorized shares will result in significant dilution for existing shareholders.
• Several directors and executive officers, including the CEO, failed to file Section 16(a) reports on a timely basis for incentive share receipts and disposals in 2024, indicating a lapse in compliance.
• The company does not have Anti-Hedging and Anti-Pledging Policies, which could expose it to additional risks related to insider trading practices.

Risks

• The proposed reverse stock split may not achieve the desired effect of increasing the stock price or maintaining Nasdaq listing compliance, potentially leading to delisting.
• A reverse stock split could decrease the liquidity of common stock due to a reduced number of outstanding shares.
• The increased proportion of authorized but unissued shares of common stock could have an anti-takeover effect, making it more difficult for shareholders to influence management or corporate control.
• The issuance of shares upon conversion of the $300 million notes will significantly dilute the percentage ownership of current shareholders.
• The company's ability to raise future capital may be hindered if shareholders do not approve the increase in authorized shares, as the convertible notes' conversion is contingent on this approval.
• Reliance on related party transactions, such as those with Doc Pharma S.A. and Maria Kozari's pharmacy, could pose conflicts of interest or expose the company to less favorable terms than arm's-length dealings.

Future Outlook

The company expects to achieve significant sales of Sky Premium Life products, mainly through Amazon channels in the UK, Singapore, Canada, and other countries. It plans to acquire Pharmacy & More within fiscal year 2025, intending to offset the outstanding receivable balance with the purchase price and establish it as the first 'shop-in-shop' for its Sky Premium Life nutraceutical products. The company also plans to actively commercialize newly licensed cancer treatment patents through research and clinical trials.

Management Comments

• Grigorios Siokas, Chairman and CEO, stated, 'We are constantly focused on improving the ways people connect with information, and believe that providing our proxy materials over the internet increases the ability of our stockholders to connect with the information they need.'
• The Board of Directors believes that the election of the nominees specified as directors is in the best interest of the Company and its stockholders and unanimously recommends a vote FOR such nominees.
• The Board of Directors believes that the authorization to effect a reverse stock split is in the best interests of the Company and our shareholders, primarily to maintain Nasdaq listing.
• The Board believes that an increase in the number of authorized shares of Common Stock and blank check Preferred Stock is in the best interest of our stockholders and our Company to support future capital raises and strategic initiatives.

Industry Context

The company operates in the pharmaceutical and nutraceutical industries, with a focus on exporting medicines and developing branded nutritional supplements (Sky Premium Life). The strategic move to acquire an exclusive worldwide license for cancer treatment patents indicates an expansion into the high-value oncology sector. The use of a significant portion of capital raise proceeds for 'Note Purchased Crypto' suggests an unusual diversification into digital assets, which is not a typical trend for a pharmaceutical company and could introduce new risk profiles.

Comparison to Industry Standards

• The company's consistent net losses and declining Total Shareholder Return (TSR) contrast sharply with the growth and profitability often seen in established pharmaceutical and nutraceutical companies, particularly those with new product development and market expansion initiatives.
• The need for a reverse stock split to maintain Nasdaq listing indicates a struggle with market valuation and investor confidence, which is not typical for healthy, growing companies in the sector.
• The significant reliance on related-party transactions, such as those with Doc Pharma S.A. and Maria Kozari's Pharmacy & More, could raise corporate governance concerns compared to industry best practices that prioritize arm's-length dealings.
• The allocation of 72.5% of capital raise proceeds to 'Note Purchased Crypto' is an unconventional strategy for a company primarily in the pharmaceutical and nutraceutical space, diverging from typical capital allocation in the industry which usually focuses on R&D, M&A, or market expansion within core competencies.

Management Changes

Corporate Governance

Related Party Transactions

• Grigorios Siokas (CEO and principal shareholder): A $1,500,000 note payable was transferred to him in 2018 and paid in full by December 31, 2022. As of December 31, 2024, there is a balance of $851,000 relating to unpaid salaries and bonuses due to him.
• Doc Pharma S.A. (CEO's wife is CEO of Doc Pharma): As of December 31, 2024, the company had a prepaid balance of $3,284,052, accounts payable of $249,768, and a receivable balance of $2,295,706 with Doc Pharma. The company purchased $1,091,540 of products and sold $781,386 of products to Doc Pharma in 2024. Agreements include a CMO agreement for manufacturing nutritional supplements, an R&D agreement for 250 nutritional supplements (with 60 additional licenses purchased for $734,921 in 2024), and a loan agreement where SkyPharm S.A. (a subsidiary) lent Doc Pharma €4,000,000, with principal repayments of $310,530 and interest income of $203,822 in 2024. On December 31, 2024, the company obtained a royalty-bearing, exclusive worldwide license for cancer treatment patents from DocPharma SA, with an initial payment of $517,550 and fixed annual payments of €350,000 for five years, plus a 1.5% royalty on net sales thereafter.
• Panagiotis Kozaris (former General Operational Manager and current employee of Cosmofarm S.A.): The company has a prepaid balance of $194,215 for shares owned, with a cumulative stock-purchase agreement intended for 2025.
• Maria Kozari (daughter of Panagiotis Kozaris, owner of Pharmacy & More): As of December 31, 2024, the company had an outstanding receivable balance of $1,183,429 from Pharmacy & More. The company plans to acquire Pharmacy & More in fiscal year 2025.
• Cana Laboratories Holding Limited: The company completed the acquisition of Cana on June 30, 2023, and a Secured Promissory Note of €4,100,000 with Cana was eliminated upon consolidation.

Stakeholder Impact

• Shareholders face significant potential dilution from the conversion of $300 million in notes and the proposed increase in authorized shares, which could negatively impact their percentage ownership and share value.
• Shareholders are also exposed to the risk of delisting from Nasdaq if the reverse stock split does not effectively raise and maintain the stock price above the minimum bid requirement.
• Employees, officers, and directors stand to benefit from the proposed 2025 equity incentive plan, which aims to align their interests with the company's success through stock-based awards.
• Institutional investors participating in the $300 million convertible note offering will gain senior secured status and conversion rights, potentially at dilutive prices for existing shareholders.
• Customers of Sky Premium Life products may see expanded availability through Amazon channels and potentially new retail points if the Pharmacy & More acquisition proceeds.
• Creditors and lenders may view the senior secured convertible notes favorably, but the company's ongoing net losses and reliance on related-party financing could be a concern.

Next Steps

• Hold the Annual Meeting of Stockholders on September 30, 2025, to vote on the proposed resolutions.
• If approved, the Board may implement a reverse stock split to regain or maintain Nasdaq listing compliance.
• If approved, the company will issue shares of common stock upon conversion of the $300 million notes.
• File a Form 8-K within four business days after the Annual Meeting to report preliminary voting results, with final results provided in an amendment if not immediately available.
• Execute a cumulative Stock Purchase Agreement (SPA) for amounts owed to Panagiotis Kozaris during 2025.
• Acquire Pharmacy & More within fiscal year 2025, intending to offset the outstanding receivable balance with the purchase price.
• Continue commercializing the exclusive worldwide license for cancer treatment patents, with fixed annual payments of €350,000 during the five-year Start-Up Term (2025-2030) and a 1.5% royalty on annual net sales thereafter.

Key Dates

Recommendation

The company exhibits several concerning indicators for investors. Persistent and significant net losses over the past three years, coupled with a substantial decline in Total Shareholder Return, point to fundamental operational challenges. The necessity of a reverse stock split to maintain Nasdaq listing signals severe market underperformance and potential delisting risk. Furthermore, the proposed $300 million convertible note offering, while providing capital, comes with substantial dilution for existing shareholders and an unusual allocation of a large portion of proceeds to 'Note Purchased Crypto,' which introduces additional, non-core business risk. The proposed massive increase in authorized shares also creates significant future dilution potential. While the company has growth initiatives, the current financial health, governance issues (late Section 16(a) filings), and the dilutive nature of the capital raise and share authorization outweigh any immediate positives, suggesting a 'sell' recommendation for seasoned investors.

Keywords

Cosmos Health, Proxy Statement, Annual Meeting, Reverse Stock Split, Convertible Notes, Equity Incentive Plan, Nasdaq Listing, Shareholder Vote, Authorized Shares, Executive Compensation, Related Party Transactions, Pharmaceuticals, Nutraceuticals, Corporate Governance